Moleculin Biotech Inc (NASDAQ:MBRX) recently announced that it will provide the needed support to enable the start of clinical studies for its new drug application at the M.D. Anderson Cancer Center, for treatment of brain tumor condition or adult glioblastoma. Moleculin is focused on developing anti-cancer drugs in which some are based on the license […]